CA3224118A1 - Pharmaceutical compositions of a b7-h3 antibody and use of the same - Google Patents
Pharmaceutical compositions of a b7-h3 antibody and use of the same Download PDFInfo
- Publication number
- CA3224118A1 CA3224118A1 CA3224118A CA3224118A CA3224118A1 CA 3224118 A1 CA3224118 A1 CA 3224118A1 CA 3224118 A CA3224118 A CA 3224118A CA 3224118 A CA3224118 A CA 3224118A CA 3224118 A1 CA3224118 A1 CA 3224118A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- pharmaceutical composition
- enoblituzumab
- composition
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222750P | 2021-07-16 | 2021-07-16 | |
| US63/222,750 | 2021-07-16 | ||
| PCT/US2022/073462 WO2023288173A1 (en) | 2021-07-16 | 2022-07-06 | Pharmaceutical compositions of a b7-h3 antibody and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3224118A1 true CA3224118A1 (en) | 2023-01-19 |
Family
ID=84920541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224118A Pending CA3224118A1 (en) | 2021-07-16 | 2022-07-06 | Pharmaceutical compositions of a b7-h3 antibody and use of the same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240336687A1 (https=) |
| EP (1) | EP4370155A4 (https=) |
| JP (1) | JP2024526773A (https=) |
| KR (1) | KR20240038005A (https=) |
| CN (1) | CN117715657A (https=) |
| AU (1) | AU2022310668A1 (https=) |
| CA (1) | CA3224118A1 (https=) |
| IL (1) | IL310187A (https=) |
| MX (1) | MX2024000690A (https=) |
| TW (1) | TW202310874A (https=) |
| WO (1) | WO2023288173A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2019246312A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| BR112022019073A2 (pt) * | 2020-03-25 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma |
-
2022
- 2022-07-06 EP EP22842996.5A patent/EP4370155A4/en not_active Withdrawn
- 2022-07-06 IL IL310187A patent/IL310187A/en unknown
- 2022-07-06 CN CN202280050225.0A patent/CN117715657A/zh active Pending
- 2022-07-06 US US18/577,945 patent/US20240336687A1/en active Pending
- 2022-07-06 KR KR1020247004914A patent/KR20240038005A/ko active Pending
- 2022-07-06 AU AU2022310668A patent/AU2022310668A1/en active Pending
- 2022-07-06 MX MX2024000690A patent/MX2024000690A/es unknown
- 2022-07-06 JP JP2024502056A patent/JP2024526773A/ja active Pending
- 2022-07-06 WO PCT/US2022/073462 patent/WO2023288173A1/en not_active Ceased
- 2022-07-06 CA CA3224118A patent/CA3224118A1/en active Pending
- 2022-07-12 TW TW111126185A patent/TW202310874A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022310668A1 (en) | 2024-01-18 |
| IL310187A (en) | 2024-03-01 |
| MX2024000690A (es) | 2024-02-07 |
| WO2023288173A1 (en) | 2023-01-19 |
| EP4370155A4 (en) | 2025-06-11 |
| JP2024526773A (ja) | 2024-07-19 |
| CN117715657A (zh) | 2024-03-15 |
| KR20240038005A (ko) | 2024-03-22 |
| US20240336687A1 (en) | 2024-10-10 |
| EP4370155A1 (en) | 2024-05-22 |
| TW202310874A (zh) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150239970A1 (en) | Stable, Low Viscosity Antibody Formulation | |
| TWI764097B (zh) | 包含抗cd47抗體的製劑及其製備方法和用途 | |
| ES2668900T3 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-Dll4 | |
| TW202206102A (zh) | Pd-l1/lag-3雙特異性抗體製劑及其製備方法和用途 | |
| CA3224118A1 (en) | Pharmaceutical compositions of a b7-h3 antibody and use of the same | |
| US12364756B2 (en) | Pharmaceutical compositions of a PD-1 antibody and use of the same | |
| US11459399B2 (en) | Pharmaceutical compositions of a HER2/neu antibody and use of the same | |
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| US20230053747A1 (en) | Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same | |
| EP4620483A1 (en) | Pharmaceutical composition comprising anti-rankl-ngf bispecific antibodies | |
| WO2022120014A1 (en) | Pharmaceutical compositions of a her2/neu antibody and use of the same | |
| HK40112469A (zh) | Pd-1抗体的药物组合物及其用途 | |
| CN116916952A (zh) | HER2/neu抗体的药物组合物及其用途 | |
| ES2702246T3 (es) | Formulaciones de agente de unión IgG4 estables | |
| HK40102521A (zh) | Her2/neu抗体的药物组合物及其用途 | |
| KR20230026407A (ko) | 액티빈 a 항체 제형 및 이의 사용 방법 | |
| TR2025000822T2 (tr) | Anti̇-cd20 anti̇kor farmasöti̇k bi̇leşi̇mi̇ ve bunun kullanimi | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
| BR112021015034B1 (pt) | Formulação de anticorpo terapêutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250610 |